Site specific nanoparticles for effective treatment of cancer: Basic concepts and strategies
DOI:
https://doi.org/10.56511/JIPBS.2020.v7.i03.pp54-58Abstract
In the recent trend of technology, the nanoparticles provide a new method of cancer drug delivery functioning as a carrier for entry through fenestrations in tumor vasculature allowing direct cell access. These nanoparticles permit exquisite changes for binding to cancer cell membranes. Therefore, the high drug doxorubicin.in addition to this the modification in folate receptor and transferrin receptor leads the cancer treatment by reduced injury of normal cells. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery. This extensive survey includes the novel approach of the drug delivery by using nanoparticle will enhance the cancer treatment
Keywords:
Drug delivery, Nanoparticles, Cancer treatmentDownloads
References
Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted treatment in oncology: current insights. International journal of nanomedicine 2015; 10:1001-18.
Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology 2018; 45:334-45.
Ferreira Ddos S, Lopes SC, Franco MS, Oliveira MC. pH-sensitive liposomes for drug delivery in cancer treatment. Therapeutic delivery 2013; 4(9):1099-123.
Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. Journal of controlled release : official journal of the Controlled Release Society 2011; 153(3):198-205.
Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of controlled release : official journal of the Controlled Release Society 2010; 148(2):135-46.
Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved in vitro efficacy on ovarian cancer cells. Cancer Research 2016; 76(14 Supplement):2065.
Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. The New England journal of medicine 2010; 363(18):17349.
Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul. 2018; 35(2):204-17.
Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced drug delivery reviews. 2002;54(5):631-51.
Jeon SI, Lee JH, Andrade JD, De Gennes PG. Protein — surface interactions in the presence of polyethylene oxide: I. Simplified theory. Journal of Colloid and Interface Science. 1991; 142(1):149-58.
Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. The Lancet Oncology 2006; 7(8):657-67.
Georgieva JV, Hoekstra D, Zuhorn IS. Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood-Brain Barrier. Pharmaceutics 2014; 6(4):557-83.
Patel P, Hanini A, Shah A, Patel D, Patel S, Bhatt P, et al. Surface Modification of Nanoparticles for Targeted Drug Delivery. In: Pathak YV, editor. Surface Modification of Nanoparticles for Targeted Drug Delivery. Cham: Springer International Publishing; 2019. p. 19-31.
Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman M, Chiappetta DA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochimica et biophysica acta. 2012; 1820(3):291-317.
Han G, Tar M, Kuppam DSR, Friedman A, Melman A, Friedman J, et al. Nanoparticles as a Novel Delivery Vehicle for Therapeutics Targeting Erectile Dysfunction. The Journal of Sexual Medicine 2010; 7(1pt1):224-33.
Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug discovery today 2012; 17(15-16):850-60.
Vhora I, Patil S, Bhatt P, Misra A. Protein – and Peptide – Drug Conjugates: An Emerging Drug Delivery Technology. In: Donev R, editor. Advances in Protein Chemistry and Structural Biology 98: Academic Press; 2015. p. 1-55.
Prassl R, Laggner P. Molecular structure of low density lipoprotein: current status and future challenges. European biophysics journal : EBJ. 2009; 38(2):145-58.
Lalani RA, Bhatt P, Rathi M, Misra A. Abstract 2063: Improved sensitivity and in vitro efficacy of RGD grafted PEGylated gemcitabine liposomes in RRM1 siRNA pretreated cancer cells. Cancer Research 2016; 76(14 Supplement):2063.
Guo XE, Ngo B, Modrek AS, Lee WH. Targeting tumor suppressor networks for cancer therapeutics. Current drug targets 2014; 15(1):216.
Addington-Hall J, McCarthy M. Dying from cancer: results of a national population-based investigation. Palliative medicine 1995; 9(4):295-305.
Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptortargeted drug delivery: current perspective and challenges. Ther Deliv. 2014; 5(9):1007-24.
Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast cancer research and treatment 2013; 137(3):807-16.
Hattori Y, Maitani Y. Folate-linked lipid-based nanoparticle for targeted gene delivery. Current drug delivery 2005; 2(3):243-52.
Published
How to Cite
Issue
Section
Copyright (c) 2020 Meghna Patel, Bhargavi Rathva
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at